<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02285634</url>
  </required_header>
  <id_info>
    <org_study_id>14-006312</org_study_id>
    <secondary_id>UL1TR000135</secondary_id>
    <nct_id>NCT02285634</nct_id>
  </id_info>
  <brief_title>The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.</brief_title>
  <official_title>The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nosebleeds (epistaxis) are a frequent cause of emergency department visits, reportedly
      inciting 1 in 200 visits. They are most common in those less than ten and older than seventy,
      often occurring in the winter months secondary to dry indoor heating. Epistaxis is associated
      with elevated blood pressures, but it is controversial whether hypertension is actual a
      contributing cause.

      In non-life-threatening epistaxis, the first step in management is commonly the application
      of a topical vasoconstrictive medication. In many cases this will lead to cessation of the
      bleeding or facilitate the exam in those that continue to bleed. Frequently used medications
      include phenylephrine, oxymetazoline, and lidocaine with epinephrine.

      Classic teaching has been to avoid the use of these medications in patients with elevated
      blood pressures due to concerns of inducing hypertensive crisis. Strict avoidance of topical
      vasoconstrictors in this patient group with epistaxis severely limits the treatment options
      for a many patients given the association between the two conditions.

      Though universally taught, the actual effect of these agents on blood pressure remains
      unquantified. Studies investigating the prevention of nose bleeding during nasotracheal
      intubations suggest that the effect might be minor with little variation between agents.

      Clinical question:

      What is the effect of commonly used intranasal vasoconstrictors on blood pressure in
      volunteers without a history of hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Actual">December 22, 2017</completion_date>
  <primary_completion_date type="Actual">December 22, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean Arterial Blood Pressure</measure>
    <time_frame>baseline, 30 minutes</time_frame>
    <description>Change in mean arterial blood pressure from the baseline measurement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood Pressure</measure>
    <time_frame>baseline, 30 minutes</time_frame>
    <description>Change from baseline in systolic blood pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diastolic Blood Pressure</measure>
    <time_frame>baseline, 30 minutes</time_frame>
    <description>Change from baseline in diastolic blood pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Heart Rate</measure>
    <time_frame>baseline, 30 minutes</time_frame>
    <description>Change from baseline in heart rate.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Epistaxis</condition>
  <condition>Blood Pressure</condition>
  <arm_group>
    <arm_group_label>Oxymetazoline 0.05%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxymetazoline 0.05%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenylephrine 0.25%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phenylephrine 0.25%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lidocaine 1% plus epinephrine 1:100,000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lidocaine 1% plus epinephrine 1:100,000</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bacteriostatic 0.9% sodium chloride (NaCL)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Bacteriostatic 0.9% NaCL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxymetazoline 0.05%</intervention_name>
    <description>sterile gauze soaked in 5 milliliters (mL) of Oxymetazoline 0.05% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
    <arm_group_label>Oxymetazoline 0.05%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine 0.25%</intervention_name>
    <description>sterile gauze soaked in 5 milliliters (mL) of Phenylephrine 0.25% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
    <arm_group_label>Phenylephrine 0.25%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine 1% plus epinephrine 1:100,000</intervention_name>
    <description>sterile gauze soaked in 5 milliliters (mL) of Lidocaine 1% plus epinephrine 1:100,000 into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
    <arm_group_label>Lidocaine 1% plus epinephrine 1:100,000</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bacteriostatic 0.9% NaCL</intervention_name>
    <description>sterile gauze soaked in 5 milliliters (mL) of Bacteriostatic 0.9% NaCL into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
    <arm_group_label>Bacteriostatic 0.9% sodium chloride (NaCL)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers over the age of eighteen that have been recently dismissed from the
             Emergency Department at Mayo Clinic Hospital, Saint Marys Campus.

          -  We will recruit a convenience sample of 100 patients from the Emergency Department who
             have completed their Emergency Department evaluation and treatment and are being
             discharged to home with non-painful conditions.

        Exclusion Criteria:

          -  We will exclude persons under the age of eighteen

          -  Vulnerable populations (pregnant patients and prisoners)

          -  Those with an allergy to any of the study agents

          -  Those with acute pain

          -  Those using antihypertensive or antiarrhythmic agents

          -  Those with significant cardiopulmonary comorbidities (namely history of arrhythmia,
             coronary artery disease, hypertension, and heart failure)

          -  Those with concomitant use of Monoamine oxidase A (MAO) Inhibitors

          -  Those with a diagnosis of angle closure glaucoma or benign prostatic hyperplasia (BPH)

          -  Those with a history of cerebrovascular disease

          -  As well as those with a history of previous nasal surgery or known nasal anatomic
             abnormalities.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Kummer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://doi.org/10.1016/j.jemermed.2018.07.004</url>
    <description>The Journal of Emergency Medicine</description>
  </link>
  <reference>
    <citation>Bellew SD, Johnson KL, Nichols MD, Kummer T. Effect of Intranasal Vasoconstrictors on Blood Pressure: A Randomized, Double-Blind, Placebo-Controlled Trial. J Emerg Med. 2018 Oct;55(4):455-464. doi: 10.1016/j.jemermed.2018.07.004. Epub 2018 Sep 6.</citation>
    <PMID>30195946</PMID>
  </reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>November 5, 2014</study_first_submitted>
  <study_first_submitted_qc>November 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2014</study_first_posted>
  <results_first_submitted>September 7, 2018</results_first_submitted>
  <results_first_submitted_qc>September 7, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 2, 2018</results_first_posted>
  <last_update_submitted>September 7, 2018</last_update_submitted>
  <last_update_submitted_qc>September 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Tobias Kummer</investigator_full_name>
    <investigator_title>Assistant Professor of Emergency Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epistaxis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy volunteers over the age of eighteen that have been recently dismissed from the Emergency Department at Mayo Clinic Hospital, Saint Marys Campus beginning 11-12-14.</recruitment_details>
      <pre_assignment_details>None to report</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oxymetazoline 0.05%</title>
          <description>Oxymetazoline 0.05%
Oxymetazoline 0.05%: sterile gauze soaked in 5 milliliters (mL) of Oxymetazoline 0.05% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
        </group>
        <group group_id="P2">
          <title>Phenylephrine 0.25%</title>
          <description>Phenylephrine 0.25%
Phenylephrine 0.25%: sterile gauze soaked in 5 milliliters (mL) of Phenylephrine 0.25% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
        </group>
        <group group_id="P3">
          <title>Lidocaine 1% Plus Epinephrine 1:100,000</title>
          <description>Lidocaine 1% plus epinephrine 1:100,000
Lidocaine 1% plus epinephrine 1:100,000: sterile gauze soaked in 5 milliliters (mL) of Lidocaine 1% plus epinephrine 1:100,000 into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
        </group>
        <group group_id="P4">
          <title>Bacteriostatic 0.9% Sodium Chloride (NaCL)</title>
          <description>Bacteriostatic 0.9% NaCL
Bacteriostatic 0.9% sodium chloride (NaCL): sterile gauze soaked in 5 milliliters (mL) of Bacteriostatic 0.9% NaCL into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oxymetazoline 0.05%</title>
          <description>Oxymetazoline 0.05%
Oxymetazoline 0.05%: sterile gauze soaked in 5 milliliters (mL) of Oxymetazoline 0.05% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
        </group>
        <group group_id="B2">
          <title>Phenylephrine 0.25%</title>
          <description>Phenylephrine 0.25%
Phenylephrine 0.25%: sterile gauze soaked in 5 milliliters (mL) of Phenylephrine 0.25% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
        </group>
        <group group_id="B3">
          <title>Lidocaine 1% Plus Epinephrine 1:100,000</title>
          <description>Lidocaine 1% plus epinephrine 1:100,000
Lidocaine 1% plus epinephrine 1:100,000: sterile gauze soaked in 5 milliliters (mL) of Lidocaine 1% plus epinephrine 1:100,000 into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
        </group>
        <group group_id="B4">
          <title>Bacteriostatic 0.9% NaCL</title>
          <description>Bacteriostatic 0.9% sodium chloride (NaCL)
Bacteriostatic 0.9% sodium chloride (NaCL): sterile gauze soaked in 5 milliliters (mL) of Bacteriostatic 0.9% NaCL into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="17"/>
            <count group_id="B5" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="17"/>
                    <count group_id="B5" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.5" spread="15.0"/>
                    <measurement group_id="B2" value="40.0" spread="16.8"/>
                    <measurement group_id="B3" value="38.6" spread="15.7"/>
                    <measurement group_id="B4" value="31.2" spread="10.1"/>
                    <measurement group_id="B5" value="36.0" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="17"/>
                    <count group_id="B5" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="17"/>
                    <count group_id="B5" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean Arterial Blood Pressure</title>
        <description>Change in mean arterial blood pressure from the baseline measurement</description>
        <time_frame>baseline, 30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxymetazoline 0.05%</title>
            <description>Oxymetazoline 0.05%
Oxymetazoline 0.05%: sterile gauze soaked in 5 milliliters (mL) of Oxymetazoline 0.05% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Phenylephrine 0.25%</title>
            <description>Phenylephrine 0.25%
Phenylephrine 0.25%: sterile gauze soaked in 5 milliliters (mL) of Phenylephrine 0.25% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
          </group>
          <group group_id="O3">
            <title>Lidocaine 1% Plus Epinephrine 1:100,000</title>
            <description>Lidocaine 1% plus epinephrine 1:100,000
Lidocaine 1% plus epinephrine 1:100,000: sterile gauze soaked in 5 milliliters (mL) of Lidocaine 1% plus epinephrine 1:100,000 into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
          </group>
          <group group_id="O4">
            <title>Bacteriostatic 0.9% NaCL</title>
            <description>Bacteriostatic 0.9% sodium chloride (NaCL)
Bacteriostatic 0.9% sodium chloride (NaCL): sterile gauze soaked in 5 milliliters (mL) of Bacteriostatic 0.9% NaCL into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Arterial Blood Pressure</title>
          <description>Change in mean arterial blood pressure from the baseline measurement</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="6.8"/>
                    <measurement group_id="O2" value="6.4" spread="5.8"/>
                    <measurement group_id="O3" value="4.6" spread="8.0"/>
                    <measurement group_id="O4" value="6.5" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.42</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.52</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.93</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systolic Blood Pressure</title>
        <description>Change from baseline in systolic blood pressure.</description>
        <time_frame>baseline, 30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxymetazoline 0.05%</title>
            <description>Oxymetazoline 0.05%
Oxymetazoline 0.05%: sterile gauze soaked in 5 milliliters (mL) of Oxymetazoline 0.05% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Phenylephrine 0.25%</title>
            <description>Phenylephrine 0.25%
Phenylephrine 0.25%: sterile gauze soaked in 5 milliliters (mL) of Phenylephrine 0.25% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
          </group>
          <group group_id="O3">
            <title>Lidocaine 1% Plus Epinephrine 1:100,000</title>
            <description>Lidocaine 1% plus epinephrine 1:100,000
Lidocaine 1% plus epinephrine 1:100,000: sterile gauze soaked in 5 milliliters (mL) of Lidocaine 1% plus epinephrine 1:100,000 into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
          </group>
          <group group_id="O4">
            <title>Bacteriostatic 0.9% NaCL</title>
            <description>Bacteriostatic 0.9% sodium chloride (NaCL)
Bacteriostatic 0.9% NaCL: sterile gauze soaked in 5 milliliters (mL) of Bacteriostatic 0.9% sodium chloride (NaCL) into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure</title>
          <description>Change from baseline in systolic blood pressure.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="9.8"/>
                    <measurement group_id="O2" value="8.2" spread="7.2"/>
                    <measurement group_id="O3" value="3.5" spread="6.5"/>
                    <measurement group_id="O4" value="8.9" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.61</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.78</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diastolic Blood Pressure</title>
        <description>Change from baseline in diastolic blood pressure.</description>
        <time_frame>baseline, 30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxymetazoline 0.05%</title>
            <description>Oxymetazoline 0.05%
Oxymetazoline 0.05%: sterile gauze soaked in 5 milliliters (mL) of Oxymetazoline 0.05% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Phenylephrine 0.25%</title>
            <description>Phenylephrine 0.25%
Phenylephrine 0.25%: sterile gauze soaked in 5 milliliters (mL) of Phenylephrine 0.25% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
          </group>
          <group group_id="O3">
            <title>Lidocaine 1% Plus Epinephrine 1:100,000</title>
            <description>Lidocaine 1% plus epinephrine 1:100,000
Lidocaine 1% plus epinephrine 1:100,000: sterile gauze soaked in 5 milliliters (mL) of Lidocaine 1% plus epinephrine 1:100,000 into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
          </group>
          <group group_id="O4">
            <title>Bacteriostatic 0.9% NaCL</title>
            <description>Bacteriostatic 0.9% sodium chloride (NaCL)
Bacteriostatic 0.9% sodium chloride (NaCL): sterile gauze soaked in 5 milliliters (mL) of Bacteriostatic 0.9% NaCL into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Diastolic Blood Pressure</title>
          <description>Change from baseline in diastolic blood pressure.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="7.7"/>
                    <measurement group_id="O2" value="7.9" spread="6.8"/>
                    <measurement group_id="O3" value="6.2" spread="8.3"/>
                    <measurement group_id="O4" value="9.3" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.27</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.17</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Heart Rate</title>
        <description>Change from baseline in heart rate.</description>
        <time_frame>baseline, 30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxymetazoline 0.05%</title>
            <description>Oxymetazoline 0.05%
Oxymetazoline 0.05%: sterile gauze soaked in 5 milliliters (mL) of Oxymetazoline 0.05% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Phenylephrine 0.25%</title>
            <description>Phenylephrine 0.25%
Phenylephrine 0.25%: sterile gauze soaked in 5 milliliters (mL) of Phenylephrine 0.25% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
          </group>
          <group group_id="O3">
            <title>Lidocaine 1% Plus Epinephrine 1:100,000</title>
            <description>Lidocaine 1% plus epinephrine 1:100,000
Lidocaine 1% plus epinephrine 1:100,000: sterile gauze soaked in 5 milliliters (mL) of Lidocaine 1% plus epinephrine 1:100,000 into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
          </group>
          <group group_id="O4">
            <title>Bacteriostatic 0.9% NaCL</title>
            <description>Bacteriostatic 0.9% sodium chloride (NaCL)
Bacteriostatic 0.9% sodium chloride (NaCL): sterile gauze soaked in 5 milliliters (mL) of Bacteriostatic 0.9% NaCL into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Heart Rate</title>
          <description>Change from baseline in heart rate.</description>
          <units>beats/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="5.2"/>
                    <measurement group_id="O2" value="5.2" spread="6.6"/>
                    <measurement group_id="O3" value="7.5" spread="9.7"/>
                    <measurement group_id="O4" value="6.8" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.78</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.10</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.47</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for the duration of the study protocol. Total observation time was 30 minutes and after completion of the study protocol any adverse effects were recorded.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oxymetazoline 0.05%</title>
          <description>Oxymetazoline 0.05%
Oxymetazoline 0.05%: sterile gauze soaked in 5 milliliters (mL) of Oxymetazoline 0.05% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
        </group>
        <group group_id="E2">
          <title>Phenylephrine 0.25%</title>
          <description>Phenylephrine 0.25%
Phenylephrine 0.25%: sterile gauze soaked in 5 milliliters (mL) of Phenylephrine 0.25% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
        </group>
        <group group_id="E3">
          <title>Lidocaine 1% Plus Epinephrine 1:100,000</title>
          <description>Lidocaine 1% plus epinephrine 1:100,000
Lidocaine 1% plus epinephrine 1:100,000: sterile gauze soaked in 5 milliliters (mL) of Lidocaine 1% plus epinephrine 1:100,000 into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
        </group>
        <group group_id="E4">
          <title>Bacteriostatic 0.9% NaCL</title>
          <description>Bacteriostatic 0.9% sodium chloride (NaCL)
Bacteriostatic 0.9% sodium chloride (NaCL): sterile gauze soaked in 5 milliliters (mL) of Bacteriostatic 0.9% NaCL into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye watering</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Diziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Unpleasant aftertaste</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The primary limitation was the small sample size as enrollment was markedly more difficult than anticipated.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Tobias Kummer</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507 255 4732</phone>
      <email>vanmeter.derek@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

